Companies / Alzamend Neuro, Inc.

Alzamend Neuro, Inc.

Nasdaq: ALZNCIK 1677077ATLANTA, GA

Financials

Revenue—
Net income$8.80M
Total debt—
Cash$710.7K
Diluted EPS$-2.63
Shares outstanding4.8M

Ownership

4.8M shares outstanding · as of Jul 22, 2026
2.4%Insiders
Ownership
Insiders2.43%116,648
Institutions5.51%263,822
Public float92.06%4,411,055

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 1

View all →
Insider% of sharesShares
Ault & Company, Inc.Director
2.43%116,648

Institutional holders 13

View all →
HolderValue% of shares
DRW Securities, LLC$211.7K2.43%
Geode Capital Management, LLC$48.4K0.95%
UBS Group AG$44.7K0.51%
Vanguard Group Inc$39.3K0.45%
Morgan Stanley$32.8K0.38%
XTX Topco Ltd$22.7K0.26%
Clearstead Advisors, LLC$18.2K0.21%
Tower Research Capital LLC (TRC)$3.8K0.04%
BlackRock, Inc.$524<0.01%
Bank of America Corp /De$78<0.01%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Apr 14, 2026Ault &amp; Company, Inc.
Director
BuyCommon Stock$108.9K+108K
+1312.20%
116,648
2.43% of shares
medium

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
ALZNCommon StockEquity02262M605BBG00ZMXG7M8